<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113381</url>
  </required_header>
  <id_info>
    <org_study_id>C-CERFLO-001</org_study_id>
    <nct_id>NCT05113381</nct_id>
  </id_info>
  <brief_title>The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of IVH</brief_title>
  <official_title>A Prospective, Multicenter Study to Evaluate the Performance and Safety of the CerebroFlo™ EVD Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integra LifeSciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Integra LifeSciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to assess the occurrence of flushing interventions to&#xD;
      address occlusions during the treatment of interventricular hemorrhage (spontaneous primary&#xD;
      IVH or secondary IVH due to ruptured aneurysm).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential study candidates will be screened for inclusion and exclusion criteria after&#xD;
      informed consent has been provided by the Legally Acceptable Representative and/or the study&#xD;
      candidate.&#xD;
&#xD;
      Once enrolled in the study, data will be collected from those subjects with elevated&#xD;
      intracranial pressure (ICP), interventricular hemorrhage, or hydrocephalic shunt infections&#xD;
      as a result of the use of the EVD catheter.&#xD;
&#xD;
      Pre-insertion and peri-removal CT scans and neurological assessment data will also be&#xD;
      collected.&#xD;
&#xD;
      Data will be collected for subjects beginning from the time of hospital admission through&#xD;
      discharge and followed by the 30 Day and 90 Day Follow up Visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of flushing interventions to address occlusions</measure>
    <time_frame>study device implantation through study device removal</time_frame>
    <description>The number of flushing interventions from initial catheter placement through catheter removal, an average of 10 days, to address occlusions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of hemorrhage volume</measure>
    <time_frame>Device implantation through to 90-Day follow-up</time_frame>
    <description>Reduction of hemorrhage volume as assessed on pre- and post-insertion of the CerebroFlo device as assessed on CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Glasgow Coma Score (GCS)</measure>
    <time_frame>Device implantation through to 90-Day follow-up</time_frame>
    <description>Assessment of Glasgow Coma Score (GCS) at Admission, Discharge, 30-Day and/or 90-Day timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Modified Rankin Score (mRS)</measure>
    <time_frame>Device implantation through to 90-Day follow-up</time_frame>
    <description>Assessment of Modified Rankin Score (mRS) at Admission, Discharge, 30-Day and/or 90-Day timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>Device implantation through to 90-Day follow-up</time_frame>
    <description>Assessment of National Institute of Health Stroke Scale (NIHSS) at Admission, Discharge, 30-Day and/or 90-Day timepoints</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Intraventricular Hemorrhage</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Intraventricular Hemorrhage Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Cerebrospinal Fluid (CSF) reduction Extra Ventricular Drainage (EVD) catheters will be used for cerebrospinal fluid drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CerebroFlo™ EVD Catheter</intervention_name>
    <description>The CerebroFlo™ EVD Catheter is indicated for temporary insertion into a ventricular cavity of the brain for external drainage of cerebrospinal fluid (CSF) in those patients with elevated intracranial pressure (ICP), intraventricular hemorrhage, or hydrocephalic shunt infections.</description>
    <arm_group_label>Intraventricular Hemorrhage Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject and/or legally authorized representative has reviewed the IRB- approved&#xD;
             consent form, has been properly consented per the protocol and has documented their&#xD;
             consent to participate in the study by signing the IRB-approved consent form.&#xD;
&#xD;
          2. Subject is ≥ 18 years of age at the time of consent.&#xD;
&#xD;
          3. Subjects with intraventricular hemorrhage (spontaneous primary IVH or secondary IVH&#xD;
             due to ruptured aneurysm) who have had CerebroFlo™ EVD Catheter(s) placed without&#xD;
             complication.&#xD;
&#xD;
          4. Subjects who require only one EVD Catheter at initial admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a scalp infection present.&#xD;
&#xD;
          2. Subjects with uncorrectable coagulopathy due to prior administration of anticoagulants&#xD;
             at the time the CerebroFlo™ EVD Catheter(s) is placed.&#xD;
&#xD;
          3. Subjects known to have a bleeding diathesis.&#xD;
&#xD;
          4. Subjects in which the CerebroFlo™ EVD Catheter(s) is placed directly into a hematoma&#xD;
&#xD;
          5. Evidence of catheter-associated hemorrhage from insertion of the CerebroFlo EVD&#xD;
             Catheter(s) on post-placement CT scan.&#xD;
&#xD;
          6. Subject is pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Tummon</last_name>
    <phone>609-936-5490</phone>
    <email>andrew.tummon@integralife.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samira Lavingia, MBA</last_name>
    <phone>732-647-5017</phone>
    <email>samira.lavingia@integralife.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melvin Field, DO</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aten Q, Killeffer J, Seaver C, Reier L. Causes, Complications, and Costs Associated with External Ventricular Drainage Catheter Obstruction. World Neurosurg. 2020 Feb;134:501-506. doi: 10.1016/j.wneu.2019.10.105. Epub 2019 Oct 25. Review.</citation>
    <PMID>31669535</PMID>
  </reference>
  <reference>
    <citation>Fargen KM, Hoh BL, Neal D, O'connor T, Rivera-Zengotita M, Murad GJ. The burden and risk factors of ventriculostomy occlusion in a high-volume cerebrovascular practice: results of an ongoing prospective database. J Neurosurg. 2016 Jun;124(6):1805-12. doi: 10.3171/2015.5.JNS15299. Epub 2015 Oct 30.</citation>
    <PMID>26517777</PMID>
  </reference>
  <reference>
    <citation>Crites L. Reducing Catheter-Related Complications with New Anti-thrombiogenic PICC. JAVA. 2015:20(4):256.</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interventricular hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

